What question did this study set out to answer?

To explore novel antiplatelet strategies that minimize bleeding risk while effectively preventing arterial thrombosis.

March 1, 2026Biomolecules & TherapeuticsOpen Access

Hemostasis-Sparing Antiplatelet Therapy: Current Concepts and Emerging Targets in Arterial Thrombosis

Q: What are the key findings of this study?

De-escalated dual antiplatelet therapy with ticagrelor monotherapy after 3 months reduced bleeding by 32% without increasing ischemic events compared to standard DAPT in high-risk PCI patients.

Q: What is the clinical evidence from this study?

Study design: Review. Population: Patients with arterial thrombosis including acute coronary syndrome or post-percutaneous coronary intervention with high bleeding risk. Intervention: De-escalated Dual Antiplatelet Therapy (e.g., ticagrelor monotherapy after 3 months DAPT) vs. Standard Dual Antiplatelet Therapy. Primary outcome: Composite ischemic outcomes including cardiovascular death, myocardial infarction, and stroke; Bleeding events defined by BARC 2-5 bleeding criteria (HR 0.68 for bleeding, p=<0.001).

Q: What does this research mean for the field?

De-escalated dual antiplatelet therapy with ticagrelor monotherapy after 3 months reduces bleeding by 32% without increasing ischemic events compared to standard DAPT in high-risk PCI patients. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Ticagrelor monotherapy after 3 months cuts bleeding ~32% vs DAPT in high-risk PCI without increasing ischemia.

HR 0.68 for bleeding
P<0.001

Why the study?

Current DAPT reduces ischemic events in arterial thrombosis but causes dose-dependent bleeding due to an inability to distinguish pathological thrombosis from physiological hemostasis.

Design

Review

Authors

JPJi Won ParkSeoul National University EOEun Bee OhSeoul National University TCTong-Shin ChangSeoul National University

Discussion

Member takes

Implication

Supports de-escalation to ticagrelor monotherapy after 3 months in high-risk PCI; reinforces potential to uncouple antithrombotic efficacy from bleeding risk.

Key Points

To explore novel antiplatelet strategies that minimize bleeding risk while effectively preventing arterial thrombosis.
Reviewed advances in platelet biology and antiplatelet therapies.
Analyzed targeted approaches at adhesion receptors and signaling nodes.
Examined early-phase clinical studies for effectiveness and safety.
New therapies selectively inhibit thrombosis while preserving hemostasis.
Early studies show minimal impact on bleeding time with effective antithrombotic outcomes.
Individualized treatment strategies are becoming standard in clinical practice.

PICO

Population

Patients with arterial thrombosis including acute coronary syndrome or post-percutaneous coronary intervention with high bleeding risk

Intervention / Comparator

De-escalated Dual Antiplatelet Therapy (e.g., ticagrelor monotherapy after 3 months DAPT) vs Standard Dual Antiplatelet Therapy

Primary Outcome

Composite ischemic outcomes including cardiovascular death, myocardial infarction, and stroke; Bleeding events defined by BARC 2-5 bleeding criteria — HR 0.68 for bleeding, p=<0.001

Main Result

Effect estimate: HR 0.68 for bleeding

Absolute Event Rate: 3.6% vs 4.8%

p-value: p=<0.001

Emerging hemostasis-sparing antiplatelet therapies targeting upstream adhesion receptors and signaling nodes offer the potential to uncouple antithrombotic efficacy from bleeding risk.

Limitations

Trials such as TWILIGHT were not powered specifically for major bleeding differences
Heterogeneity in bleeding risk and ischemic risk assessment across studies
Long-term efficacy and safety of hemostasis-sparing agents remain under investigation
No conclusive human studies have shown definitive bleeding reduction with novel reversible P2Y12 inhibitors
Most new agents are in early phase trials or preclinical stages

Cite This Study

Park et al. (2026) conducted a review in Patients with arterial thrombosis including acute coronary syndrome or post-percutaneous coronary intervention with high bleeding risk. De-escalated Dual Antiplatelet Therapy (e.g., ticagrelor monotherapy after 3 months DAPT) vs. Standard Dual Antiplatelet Therapy was evaluated on Composite ischemic outcomes including cardiovascular death, myocardial infarction, and stroke; Bleeding events defined by BARC 2-5 bleeding criteria (HR 0.68 for bleeding, p=<0.001). De-escalated dual antiplatelet therapy with ticagrelor monotherapy after 3 months reduced bleeding by 32% without increasing ischemic events compared to standard DAPT in high-risk PCI patients.

synapsesocial.com/papers/69a3d7baec16d51705d2df37 https://doi.org/10.4062/biomolther.2025.214

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Implication

Supports de-escalation to ticagrelor monotherapy after 3 months in high-risk PCI; reinforces potential to uncouple antithrombotic efficacy from bleeding risk.

Hemostasis-Sparing Antiplatelet Therapy: Current Concepts and Emerging Targets in Arterial Thrombosis

Discussion

Member takes

Implication

Key Points

PICO

Main Result

Limitations

Cite This Study

Topics

Hemostasis-Sparing Antiplatelet Therapy: Current Concepts and Emerging Targets in Arterial Thrombosis

Discussion

Member takes

Implication

Key Points

PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider